Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53–MDM2 Interaction and the NF-κB Pathway
- 24 January 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (3), 567-577
- https://doi.org/10.1021/jm401800k
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Awakening guardian angels: drugging the p53 pathwayNature Reviews Cancer, 2009
- Blinded by the Light: The Growing Complexity of p53Cell, 2009
- Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domainCell Cycle, 2008
- Targeted rescue of a destabilized mutant of p53 by an in silico screened drugProceedings of the National Academy of Sciences of the United States of America, 2008
- Structural Biology of the Tumor Suppressor p53Annual Review of Biochemistry, 2008
- p53 in health and diseaseNature Reviews Molecular Cell Biology, 2007
- Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated MutantsPublished by Elsevier BV ,2007
- Regulating the p53 pathway: in vitro hypotheses, in vivo veritasNature Reviews Cancer, 2006
- Surfing the p53 networkNature, 2000
- p53, the Cellular Gatekeeper for Growth and DivisionCell, 1997